Login / Signup

Cysteine carboxyethylation generates neoantigens to induce HLA-restricted autoimmunity.

Yue ZhaiLiang ChenQian ZhaoZhao-Hui ZhengZhi-Nan ChenHui-Jie BianXu YangHuan-Yu LuPeng LinXi ChenRuo ChenHao-Yang SunLin-Ni FanKun ZhangBin WangXiu-Xuan SunZhuan FengYu-Meng ZhuJian-Sheng ZhouShi-Rui ChenTao ZhangSi-Yu ChenJun-Jie ChenKui ZhangYan WangYang ChangRui ZhangBei ZhangLi-Juan WangXiao-Min LiQian HeXiang-Min YangGang NanRong-Hua XieLiu YangJing-Hua YangPing Zhu
Published in: Science (New York, N.Y.) (2023)
Autoimmune diseases such as ankylosing spondylitis (AS) can be driven by emerging neoantigens that disrupt immune tolerance. Here, we developed a workflow to profile posttranslational modifications involved in neoantigen formation. Using mass spectrometry, we identified a panel of cysteine residues differentially modified by carboxyethylation that required 3-hydroxypropionic acid to generate neoantigens in patients with AS. The lysosomal degradation of integrin αIIb [ITGA2B (CD41)] carboxyethylated at Cys96 (ITGA2B-ceC96) generated carboxyethylated peptides that were presented by HLA-DRB1*04 to stimulate CD4 + T cell responses and induce autoantibody production. Immunization of HLA-DR4 transgenic mice with the ITGA2B-ceC96 peptide promoted colitis and vertebral bone erosion. Thus, metabolite-induced cysteine carboxyethylation can give rise to pathogenic neoantigens that lead to autoreactive CD4 + T cell responses and autoantibody production in autoimmune diseases.
Keyphrases